

Medical Department
Pfizer Australia Pty Limited
38-42 Wharf Road
West Ryde 2114 NSW, Australia
ABN 50 008 422 348
Tel 61 2 9850 3771 Fax 61 2 9850 3131



Pfizer Australia

Dr Bill Ketelbey
Senior Medical Director
Pfizer Australia

19 May 2008

Dear Hospital Pharmacist

RE: FRAGMIN® INJECTION (DALTEPARIN SODIUM) STOCK SUPPLY

With reference to the Australian recall of some batches of Clexane® (enoxaparin sodium), as advised in the Therapeutic Goods Administration (TGA) alert on 22 April 2008, Pfizer's current supplies of intravenous heparin and Fragmin have been tested and are free from contamination.

As a result of the recall in Australia and elsewhere, worldwide demand for Fragmin has significantly exceeded demand forecasts and at this stage it is unknown when heparin global supply will return to normal. Pfizer Australia is collaborating with the TGA to manage our limited supply of Fragmin. Prior to the recall, Pfizer Australia supplied less than 10% of the total Australian market for Low Molecular Weight Heparin. It is important to note that in the short term we will be managing the supply of Fragmin based on normal (i.e. pre-enoxaparin sodium recall) supply volumes.

Should you have any further queries on Fragmin, please contact our Medical Information Service on 1800 675 229. Fragmin order enquiries should be directed to Customer Service on 1800 629 921.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Bill Ketelbey".

Dr Bill Ketelbey
Senior Medical Director